Biogened (WAR:BGD) Other Current Liabilities: zł3.7 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BGD Biogened SA WAR:BGD
73 GF Score
Price zł20.00
GF Value zł24.12
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biogened Other Current Liabilities?

Biogened WAR:BGD +4.71% 73 Other Current Liabilities is zł3.7 Mil as of Mar. 2026. GuruFocus rates WAR:BGD with a GF Score™ of 73/100 and a GF Value™ of zł24.12 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Biogened's other current liabilities for the quarter that ended in Mar. 2026 was zł3.7 Mil.

Biogened's quarterly other current liabilities declined from Sep. 2025 (zł4.7 Mil) to Dec. 2025 (zł3.7 Mil) and declined from Dec. 2025 (zł3.7 Mil) to Mar. 2026 (zł3.7 Mil).

Biogened's annual other current liabilities declined from Dec. 2023 (zł4.6 Mil) to Dec. 2024 (zł3.9 Mil) and declined from Dec. 2024 (zł3.9 Mil) to Dec. 2025 (zł3.7 Mil).

Biogened Other Current Liabilities Related Terms

Biogened Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Biogened's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogened Other Current Liabilities Chart

Biogened Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.11 3.83 4.56 3.88 3.71

Biogened Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.03 9.04 4.66 3.71 3.71
WAR:BGD
73GF Score
Biogened SA WAR:BGD
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogened Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of zł3.7 Mil mean?
Biogened (WAR:BGD) has a Other Current Liabilities of zł3.7 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Biogened.
Is Biogened's Other Current Liabilities too high?
Biogened's current Other Current Liabilities is zł3.7 Mil. Overall, Biogened has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's Other Current Liabilities compare to ZTS and UTHR?
Biogened's Other Current Liabilities of zł3.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Biogened. Biogened's current Other Current Liabilities is zł3.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł24.12, compared to a current price of zł20.00 — trading 17.1% below its estimated fair value. The current Other Current Liabilities is zł3.7 Mil. Biogened's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Biogened (WAR:BGD), the current Other Current Liabilities is zł3.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogened (WAR:BGD) Overvalued in 2026?

Based on GuruFocus' analysis, Biogened stock appears to be undervalued. The current stock price of zł20.00 is trading 17.1% below its estimated GF Value™ of zł24.12. GuruFocus considers Biogened to be Modestly Undervalued.

Key valuation signals for WAR:BGD:

  • Other Current Liabilities: zł3.7 Mil
  • GF Value™: zł24.12 vs. price of zł20.00 (17.1% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogened Business Description

Address Ulica Pojezierska 99, Lodz, POL, 91-342
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
73GF Score

Get the complete analysis for WAR:BGD

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł20.00
Price
zł24.12
GF Value